Latest Breaking News On - Company biologic license application - Page 1 : vimarsana.com

Share this article Share this article NEW YORK, April 13, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ( Provention or the Company ) (NASDAQ: PRVB).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Provention and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On April 8, 2021, Provention issued a press release announc[ing] that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company s Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.  

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyProvention bio incCompany biologic license applicationDrug administrationPomerantz firmProvention bioBiologic license applicationPomerantz llpபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்